Don't price retail at will, the health insurance bureau will strictly control it!

[industry trends of pharmaceutical network] on December 6, the State Health Insurance Bureau launched a special seminar on the construction of integrity system and punishment system in the centralized procurement of public hospitals for all kinds of disorders in the pharmaceutical industry On the same day of the meeting, the opinions on the current drug price management was officially released, which clearly stated that the monitoring and early warning, correspondence and interview, cost investigation, warning and credit evaluation will be comprehensively used to establish a regulatory mechanism for the normalization of drug prices, and Credit Incentive and punishment will be taken as an important means to play the role of the government Photo source: in addition, the opinion also stressed that medical insurance should play a leading role in drug prices, adhere to the direction of "volume purchase, volume price linkage, and integration of bidding and procurement", and promote the return of drug prices to a reasonable level In addition, we should improve the agreement management of designated institutions, strengthen the price supervision and information disclosure of drugs paid by medical insurance funds, and positively guide the market price order It is worth noting that, if the above requirements are met, in addition to the reasonable formulation of drug prices, the medical insurance bureau will also manage drug prices through centralized purchase, medical insurance payment and other ways In view of the current situation, it may be understood that drugs with high prices can be reduced In fact, the medical insurance bureau has taken action to control the drug price for a long time Not to mention volume purchase and negotiation, the purchase and pricing of retail pharmacies have been gradually unified since this year For example, in May, Shandong Pharmaceutical centralized purchase issued a notice to specify the designated chain retail drugstores, which can purchase drugs online on Shandong Pharmaceutical centralized purchase platform In July, Shanghai Institute of Pharmaceutical Affairs carried out "open price negotiation for drugs limited to pharmacies on the Internet in an all-round way", requiring manufacturers to fill in the "purchase price of 15 provinces and cities" After approval, it was pushed to designated pharmacies in batches according to steps to carry out price negotiation
Not long ago, in order to improve the market competition mechanism of drug prices, protect the insured people's right to know, to supervise and to choose drug prices, and to guide the operators to make reasonable drug prices, Quanzhou Medical Insurance Bureau issued a new measure for the convenience of the people It established the monitoring and release system of retail price information of commonly used drugs, which covers 100 kinds of chain retail pharmacies designated by 15 medical insurance in Quanzhou The price of commonly used drugs shall be monitored, and the retail price of drugs shall be updated and announced on a quarterly basis, so that the masses can inquire the price information of various drugs in a timely manner Through the "price ratio of three", choose retail pharmacies to purchase drugs, reduce the burden of drug use In fact, since its establishment, the National Health Insurance Bureau has concentrated on pricing, bidding procurement and supervision functions, but in the past, the management of drug pricing mainly focused on medical institutions From the current performance of the functions of the state health insurance bureau, it is an inevitable result for the management of drug prices to penetrate from hospitals to the retail market On the basis of ensuring market competition, the prices of commonly used drugs in retail pharmacies will inevitably be supervised in the future, especially the market behaviors such as monopoly price increase and collusion price increase will also be severely punished In the future, with the gradual implementation of regulatory functions, drug pricing and medical insurance fund management in the retail market will also be subject to comprehensive supervision, and can no longer be arbitrarily priced or increased, so as to truly guarantee the medical demand of the masses and reduce the burden of medical expenses.